ALS Unfiltered is a series of live expert-led presentations and candid conversations on ALS, current drug research, clinical
trials, ALS resources and more. Hosted by ALS experts and scientists from the ALS Therapy Development Institute, ALS
Unfiltered sessions are scheduled in a number of cities across the US during 2019. There is no cost to attend!
Each session is interactive and includes the following topics, among others:
- What do people with ALS currently do to fight back?
- Stem cells, ASOs, small molecule drugs, and other potential treatments for ALS.
- Precision Medicine as the future of drug development for neuroscience.
- Genetics and ALS: what do we know so far?
- ALS TDI's strategy to #EndALS.
ALS Unfiltered sessions will take place across the country in 2019. If you would like us to hold an event in your area, please contact
us at firstname.lastname@example.org
Upcoming ALS Unfiltered Events
San Diego, CA
Thursday, April 4, 2019 | 5:00 - 8:00pm The Point, 1010 Santa Clara Pl, San Diego, CA 92109
Steve Perrin, ALS Therapy Development Institute
Dr. Steven Perrin is currently the Chief Executive Officer and Chief Scientific Officer at the ALS Therapy Development Institute (ALS TDI)
in Cambridge, MA. He earned his Ph.D. at Boston University Medical Center studying the transcriptional regulation of genes during adipocyte
and myocyte differentiation. Steven moved into the pharmaceutical industry in 1997 holding positions at the Hoechst-Ariad Genomics Center,
Aventis Pharmaceuticals and more recently as Director of Molecular Profiling at Biogen Idec. Steven joined ALS TDI in 2007 as part of
historical collaboration between the Muscular Dystrophy Association, Augie's Quest and ALS TDI to develop effective therapeutics for ALS
patients. Since joining ALS TDI Steven has spearheaded the development of computational biology capabilities and information management
systems to more clearly understand the molecular mechanisms associated with disease onset and progression in neurodegenerative diseases. He
has expanded ALS TDI's drug screening program to include expertise in the generation and assessment of gene therapy vectors and protein
biologics in preclinical models of neurodegeneration. He has developed a business plan to facilitate pharmaceutical partnerships for rapid
clinical development and commercialization of promising targets for ALS patients. Steven is a frequent participant in international conferences
in computational biology, genomics, drug development, and neurodegeneration.
Google Directions Register